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Abstract
 
Interleukin (IL)-13 has recently been shown to play important and unique roles in asthma, par-
asite immunity, and tumor recurrence. At least two distinct receptor components, IL-4 recep-
tor (R)
 
  
 
and IL-13R
 
 
 
1, mediate the diverse actions of IL-13. We have recently described an
additional high affinity receptor for IL-13, IL-13R
 
 
 
2, whose function in IL-13 signaling is un-
known. To better appreciate the functional importance of IL-13R
 
 
 
2, mice deficient in IL-
13R
 
 
 
2 were generated by gene targeting. Serum immunoglobulin E levels were increased in
 
IL-13R
 
 
 
2
 
 
 
/
 
  
 
mice despite the fact that serum IL-13 was absent and immune interferon 
 
  
 
pro-
duction increased compared with wild-type mice. IL-13R
 
 
 
2–deficient mice display increased
bone marrow macrophage progenitor frequency and decreased tissue macrophage nitric oxide
and IL-12 production in response to lipopolysaccharide. These results are consistent with a
phenotype of enhanced IL-13 responsiveness and demonstrate a role for endogenous IL-13 and
IL-13R
 
 
 
2 in regulating immune responses in wild-type mice.
Key words: receptors • immunoglobulin E • interleukin 13 • knockout mice • nitric oxide
 
Introduction
 
Expression of Th2 cytokines such as IL-4, IL-5, IL-9, and
IL-13, and inflammation are strongly associated with para-
sitic infections and asthma (1, 2). For this reason, significant
effort has been focused on understanding the contribution
of individual Th2 cytokines and their receptors to disease
progression in animal models. Within this family of cyto-
kines, IL-13 has recently been shown to play a necessary
role in protective immunity against nematodes and a detri-
mental role in immune responses associated with schistoso-
miasis and asthma (3–6).
Receptor binding chains for IL-13 include IL-13R
 
 
 
1
and IL-13R
 
 
 
2 (7–10). IL-13R
 
 
 
1 binds IL-13 with low
affinity. Coexpression of IL-13R
 
 
 
1 with IL-4R
 
  
 
results in
the formation of a high affinity receptor signaling complex
(8, 9, 11). This receptor complex is widely expressed on
both lymphoid and nonlymphoid cells and can also be acti-
vated by IL-4, thus accounting for the significant overlap in
IL-4 and IL-13 activities (12). In contrast to IL-13R
 
 
 
1, IL-
13R
 
 
 
2 selectively binds IL-13 with high affinity and its
contribution to IL-13 signaling is unknown. The cytoplas-
mic region of murine IL-13R
 
 
 
2 does not posses an obvi-
ous signaling motif or Janus kinase/signal transducer and
activator of transcription (STAT)
 
* 
 
binding sequence (10).
Expression of IL-13R
 
 
 
2 transcripts are restricted to spleen
and brain and in contrast to IL-13R
 
 
 
1, a soluble form of
this receptor has been detected in mouse serum (13). Simi-
lar to the IL-1 type II receptor (14), IL-13R
 
 
 
2 may func-
tion as a decoy to attenuate IL-13 effects in vivo.
IL-13 has been shown to have many different activities
on numerous cell types. In vitro studies of antigen-present-
ing cells have demonstrated that IL-13 generally inhibits
activation-induced cytokine and nitric oxide (NO) pro-
duction from macrophages (15–17) and increases IgE pro-
 
Address correspondence to Debra D. Donaldson, Wyeth Research, 200
CambridgePark Drive, Cambridge, MA 02140. Phone: 617-665-5549;
Fax: 617-665-5584; E-mail: ddonaldson@wyeth.com
 
*
 
Abbreviations used in this paper: 
 
EMSA, electrophoretic mobility shift as-
say; MLF, murine lung fibroblasts; NO, nitric oxide; RPA, RNase pro-
tection assay; RPM, resident peritoneal macrophages; STAT, signal trans-
ducer and activator of transcription.T
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IL-13R
 
 
 
2–deficient Mice
 
duction from human B cells (18). In addition, administra-
tion of rIL-13 in vivo or transgenic overexpression of IL-13
leads to the enhancement of both macrophage develop-
ment and IgE production and affords protection to LPS-
induced endotoxemia (4, 19–23).
To understand the role of IL-13R
 
 
 
2 in regulating the
biologic responses to IL-13, we examined the effect of a
targeted deletion of IL-13R
 
 
 
2. IL-13R
 
 
 
2–deficient mice
display enhanced macrophage development and IgE pro-
duction consistent with the notion that IL-13R
 
 
 
2 can
serve to limit IL-13 responses in vivo.
 
Materials and Methods
 
Animals.
 
A gene targeting vector was designed such that ho-
mologous recombination would delete the translation initiation
site and signal peptide of the endogenous gene encoding IL-
13R
 
 
 
2. Male 
 
IL-13R
 
 
 
2
 
 
 
/
 
  
 
mice were generated from (129 
 
 
 
C57BL/6) mice and were backcrossed onto the BALB/c strain.
BALB/c littermates at the identical stage of backcrossing between
8–14 wk of age were used within each experiment. Littermates
after three to four generations were used in histopathology studies
and biochemical studies (see Fig. 2). Littermates after 8–10 gener-
ations were used in functional assays (see Figs. 3–5). Animals were
maintained under pathogen-free conditions in accordance with
guidelines from the Committee on Animals of the Harvard Med-
ical School and Wyeth Research, National Research Council,
and the American Association for the Accreditation of Laboratory
Animal Care.
 
Western Blotting.
 
Pooled sera was diluted with one volume of
cell lysis buffer (Tris buffered saline: 20 mM Tris, 150 mM NaCl,
pH 7.5; 1% Triton X-100, 40 mg iodoacetamide per 25 ml, and 1
tablet of protease inhibitor cocktail; Boehringer). Three to five
million cells were lysed in 1.5 ml lysis buffer. IL-13R
 
 
 
2 was pre-
cipitated with 2.5 
 
 
 
g biotinylated Chinese hamster ovary murine
IL-13 (4) and streptavidin agarose beads (Pierce Chemical Co.).
After washing, samples were subjected to 12% SDS-PAGE and
transferred to polyvinylidene difluoride (NEN Life Science Prod-
ucts) by semidry electroblotting. The blot was incubated with
polyclonal rabbit sera to murine IL-13R
 
 
 
2 (5 
 
 
 
g/ml; 24). Perox-
idase-labeled goat anti–rabbit IgG (1:20,000; Jackson Immu-
noResearch Laboratories) was added as a second step. The blot
was developed with enhanced chemiluminescence reagents and
exposed on Hyperfilm (Amersham Biosciences).
 
Electrophoretic Mobility Shift Assay (EMSA).
 
Cells were cul-
tured on 60 
 
  
 
15–mm plates in complete media until 85% con-
fluent. Cells were washed twice with RPMI and incubated in
RPMI for 1.5 h before stimulation with cytokines. Cytokines
were added for 15 min and the adherent murine lung fibroblasts
(MLF) were harvested with trypsin and washed once with ice-
cold PBS. The cells were lysed in 3 packed volumes with lysis
buffer (20 mM Hepes-HCl, 20% glycerol, 500 mM KCl, 0.5
mM DTT, 1 mM sodium orthovanadate, 5 mM sodium fluoride,
0.2 mM EDTA, 0.1% Triton X-100, and one-half protease in-
hibitor tablet; Boehringer). The protein concentration from the
whole cell extract was determined by micro bicinchonic acid
(Pierce Chemical Co.). 10 
 
 
 
m protein was mixed with 4 
 
 
 
g
poly dI-dC (Amersham Biosciences), 5
 
  
 
gel shift buffer (20 mM
Hepes, pH 7.9, 50 mM KCl, 10% glycerol, 0.5 mM DTT, and
0.1 mMEDTA), and anti-STAT1 or anti-STAT6 (Santa Cruz
Biotechnology, Inc.) Ab in a total volume of 14 
 
 
 
l. The mixture
was incubated for 2 h at 4
 
 
 
C. The STAT6-specific radiolabeled
 
probe (25,000 cpm in 1 
 
 
 
l; reference 25) was added for 20 min
at 30
 
 
 
C. The samples were electrophoresed on a 5% polyacryl-
amide gel in 0.5
 
  
 
Tris-glycine buffer. The gel was dried before
film exposure.
 
RNase Protection Assay (RPA).
 
MLF were grown in medium
with or without murine IL-4 or murine IL-13 (R&D Systems) at
10 ng/ml. RNA was isolated at 4 and 24 h using the QIAGEN
RNeasy mini purification kit. Two micrograms RNA per sample
were used for analysis of receptor expression in the mCR-1 Ri-
boQuant Multiprobe RPA (BD Biosciences). Note that the tech-
nical data sheet for mCR-1 assigns the name IL-13R
 
 
 
2 to the
template derived from IL-13R
 
 
 
1. To study IL-13R
 
 
 
2 in this
system we generated a 206-bp template (including 32 bp vector
sequence) in vitro by inserting bases 973–1129 of IL-13LR
 
 
 
2
(sequence data available from GenBank/EMBL/DDBJ under ac-
cession no. NM_008356) into pGEM-3Zf(
 
 
 
) (Promega). 
 
32
 
P-
labeled antisense probe was synthesized by T7 RNA polymerase
from IL-13R
 
 
 
2 template in combination with the mCR-1 tem-
plate. The 172-bp protected probe for IL-13
 
 
 
2 was easily re-
solved from IL-2R
 
  
 
(190 bp) and L32 (141 bp) probes on dena-
turing polyacrylamide gels followed by autoradiography at
 
 
 
70
 
 
 
C overnight.
 
Culture of Ba/F3, Ba/F3.IL-13R
 
 
 
2, Ba/F3.IL-13R
 
 
 
1, IL-
13R
 
 
 
2
 
    
 
MLF, and IL-13R
 
 
 
2
 
    
 
MLF.
 
Culture of Ba/F3
lines has been described (10). MLF were isolated from lung ex-
plants and enriched by repeated passage in vitro. In brief, the lung
was harvested, minced, and incubated in trypsin solution for 1 h
at 37
 
 
 
C. The MLF were cultured on human collagen–coated
plastic at 12.5 
 
 
 
g/ml (Biomedical Technologies Inc.) in MEM
containing 20% FBS, 1% MEM vitamins, 1% MEM nonessential
amino acids, 1% antibiotic/antimycotic (GIBCO BRL), 10 U/ml
heparin, 154 
 
 
 
g/ml endothelial mitogen (BTI), and 5 
 
  
 
10
 
 
 
5
 
 M
2-ME. MLF were used at passage 15.
 
Peritoneal Cell Preparation and Stimulation In Vitro.
 
Resident
peritoneal cells were harvested by peritoneal lavage using 7 ml
cold PBS. Cell concentration was adjusted such that 5 
 
  
 
10
 
4
 
CD11b
 
  
 
(BD Biosciences) macrophages were adhered per well in
a 96-well plate. After a 2-h incubation at 37
 
 
 
C, 5% CO
 
2
 
, the
nonadherent cells were removed by rinsing several times with
RPMI without serum. Macrophages were then cultured in se-
rum-free RPMI supplemented with antibiotics, 10
 
 
 
2 
 
M mor-
pholinopropane sulfonic acid (buffer), 5 
 
  
 
10
 
 
 
5
 
 M 2-ME, 2.5
mg/ml BSA, 10 
 
 
 
g/ml transferrin, and 1 
 
 
 
U/ml insulin
(GIBCO BRL).
 
Measurement of NO and Cytokine Production.
 
Macrophages
(prepared as described above) were cultured with 20 ng/ml IFN-
 
 
 
(R&D Systems) and 20 ng/ml LPS (Sigma-Aldrich). Supernatants
were harvested after 48 h. Nitrite, as an indicator of NO produc-
tion, was determined spectrophotometrically by using the stan-
dard Griess reaction with sodium nitrite used as a standard. In
brief, 50 
 
 
 
l supernatant was mixed with 50 
 
 
 
l of 1% sulfanil-
amide and 50 
 
 
 
l of 0.1% napthylethylenediamine dihydrochlo-
ride. Absorbence was measured at 550 nm using an automated
plate reader. Cytokines were measured by ELISA (R&D Sys-
tems). IL-13 was used at concentrations noted in the figures. Cells
were treated with IL-13 for 16–20 h before the addition of
IFN-
 
  
 
and LPS.
 
Cytokine Production Assays.
 
Spleens were harvested aseptically
and single cell suspensions were prepared and erythrocytes were
lysed using ammonium chloride. 2 ml cells at a concentration of
4 
 
  
 
10
 
6 
 
cells/ml in RPMI containing 100 U penicillin/ml, 100
 
 
 
g streptomycin/ml, 2 mM glutamine, 5 
 
  
 
10
 
 
 
5 M 2-ME, and
10% FCS were plated in 24-well tissue culture plates (Costar).T
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Cells were incubated alone or stimulated with 0.1 ug/ml anti-
CD3 (BD Biosciences) or 1 ug/ml LPS. Supernatants were col-
lected at 72 h and stored at  20 C until analyzed. Cytokines
were measured by ELISA (R&D Systems).
Ig Subclass ELISAs. ELISA plates (MaxiSorp; Nunc) were
coated overnight at 4 C with goat anti–mouse    light chain
(Sigma-Aldrich) for IgM, IgA, and IgG3 assays, goat anti–mouse
IgG, Fab specific (Sigma-Aldrich) for IgG2a and IgG1, goat anti–
mouse IgG, Fc specific (Sigma-Aldrich) for IgG2b, and rat anti–
mouse IgE (BD Biosciences) for IgE. All incubations were per-
formed for 1–2 h at room temperature. Plates were blocked with
0.5% gelatin in PBS, washed in PBS containing 0.05% Tween-20
(PBS-Tween), and incubated with purified mouse Igs (BD Bio-
sciences) as standards or with serum dilutions. Specificity was
achieved with the appropriate biotinylated antibodies to IgM,
IgA, IgG2a, IgG2b, IgG3 (Southern Biotechnology Associates,
Inc.), IgG1, or IgE (BD Biosciences) and use of mouse IgG or
IgM antibodies (Sigma-Aldrich) for blocking. Binding was de-
tected with peroxidase-linked streptavidin (Southern Biotechnol-
ogy Associates, Inc.) and tetramethylbenzidine substrate (Kirke-
gaard and Perry Labs.).
Serum IL-13 ELISA. Mouse IL-13 ELISA kits were pur-
chased from R&D Systems. Assays were performed according to
the manufacturer’s instructions, with the exception that 100  g/
ml rabbit IgG anti–IL-13R 2 Ab (24) was added during the pri-
mary incubation period to a 1:10 or 1:100 dilution of serum sam-
ples and incubated overnight at 4 C to dissociate IL-13 from se-
rum IL-13R 2. Duplicate serum samples were examined from
each animal. OD readings were converted to pg/ml using a stan-
dard curve and the appropriate dilution factor.
Preparation of Tissue Extracts. Excised lung and liver were
weighed, homogenized, and freeze/thawed as previously de-
scribed except that a Brinkmann homogenizer was used (26).
Homogenates were centrifuged in a microfuge at 4 C and the su-
pernatants were used for the measurement of cytokines.
MethoCult Colony Assay. Bone marrow was obtained from
the femurs of three IL-13R 2    and IL-13R 2 /  mice. Bone
marrow cells were washed twice with DME plus 10% FCS and
counted in methylene blue. Cells were plated at 105 cells/ml in
MethoCult complete media containing 1% BSA and growth fac-
tors (insulin, transferrin, IL-3, IL-6, stem cell factor, and erythro-
poietin; StemCell Technologies Inc.) in triplicate in 12-well clus-
ter dishes at 1 ml/well. Cultures were grown for 6 d and colonies
were counted through an inverted phase contrast microscope.
Colonies were differentiated based on phenotype: large uni-
formly red colonies, burst forming unit erythroid; mixed colonies
including granuloctye, erythrocyte, macrophage, and megakaryo-
cyte; and large, diffuse colonies composed of only macrophages.
Statistical Analysis. Significance was assessed with Student’s
unpaired, two-tailed t test. P values  0.05 were considered to be
significant.
Results
Generation of IL-13R 2    Mice. IL-13R 2 /   mice
were viable, fertile, and displayed no overt abnormalities
in appearance, weight, nor behavior. Examination of se-
rum from IL-13R 2 /  mice failed to reveal soluble IL-
13R 2 capable of binding IL-13 demonstrating that the
mice lack IL-13R 2 (Fig. 1). Detailed necropsy including
histopathology, serum chemistry, and hematology did not
reveal any obvious abnormalities. FACS® analysis of cell
suspensions from lymphoid and hematopoietic tissues of
wild-type mice failed to show differences in cell number
nor expression levels for: CD3, CD90, CD45, CD69,
CD4, and CD8 on thymocytes; CD45, B220, CD23,
CD11b, CD11c, CD3, CD4, CD8, and class I and II on
splenocytes; CD45, Gr-1, Ter-119, CD11b, and B220 on
bone marrow cells; CD3, CD5, CD8, B220, CD4,
CD19, CD23, and CD11b on peripheral blood cells; and
CD16/32, CD14, CD5, CD19, CD3, and class I and II
on peritoneal cells.
STAT6 Signaling Is Preserved in Fibroblasts from IL-
13R 2    Mice. IL-13 activates STAT6 in fibroblasts (27)
and fibroblasts play an important role in chronic immune
responses. Therefore, we examined the expression of IL-
13R components in MLF from wild-type mice. Passage 15
MLF were stimulated with IL-13 or IL-4 and examined for
receptor expression using RPA. Fig. 2 A shows that MLF
express IL-13R 1 and IL-4R  transcripts without stimula-
tion and IL-13R 2 within 4 (unpublished data) or 24 h af-
ter the addition of IL-13 or IL-4. Low levels of IL-13R 2
transcripts are detected at early passages in MLF culture by
RPA without stimulation (unpublished data). Fig. 2 B
shows that MLF derived from IL-13R 2 /   and  IL-
13R 2 /  mice exposed to IL-13 display STAT6 activa-
tion as measured by EMSA assay. Complementing the re-
sults of Kawakami et al. (28) and Murata et al. (11), these
results show that in MLF, IL-13R 2 is not required for IL-
13–induced STAT6 activation.
Serum, Tissue, and Immune Activation Levels of IL-13 in IL-
13R 2    and IL-13R 2    Mice. We have previously
demonstrated the presence of IL-13 in wild-type and para-
site-infected mouse serum using a modified ELISA (24).
The ELISA specifically minimizes the quenching effect of
IL-13R 2 and measures total IL-13 in wild-type serum.
To study the effect of IL-13R 2 deficiency on serum IL-
13 levels we measured the levels of IL-13 in the serum in
IL-13R 2 /  and IL-13R 2 /  mice. Fig. 3 A shows that
IL-13R 2 /  mice had greatly reduced or undetectable
levels of serum IL-13 compared to IL-13R 2 /  mice,
which had average serum levels of 90 pg/ml. To ascertain
that the loss of IL-13 expression in the serum was not due
to lack of IL-13 production in IL-13R 2 /  mice, we
evaluated the results of polyclonal stimulation of spleen
Figure 1. Generation of IL-13R 2 / 
mice. Analysis of IL-13R 2 expression
from serum. Sera was pooled from four
IL-13R 2 /   and four IL-13R 2 / 
male mice. IL-13R 2 was precipitated
and detected by western with rabbit poly-
clonal antisera to recombinant IL-13R 2.
Lysed Ba/F3.IL-13R 2 (reference 10)
cells were used as a positive control. The
bottom arrow indicates murine IL-13R 2
precipitated from the sera of IL-13R 2 / 
but not IL-13R 2 /  mice. The top ar-
row identifies IL-13R 2 precipitated
from Ba/F3.IL-13R 2 lysate. The non-
specific band at 65 kD was also present in
parental Ba/F3 cells (unpublished data).T
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706 IL-13R 2–deficient Mice
cells with CD3 or LPS. Fig. 3 B shows that anti-CD3–
stimulated spleen cells from IL-13R 2 /  mice produce
IL-13 at a level only slightly lower than IL-13R 2 / 
mice. Matsukawa et al. (26) previously demonstrated the
presence of IL-13 in tissue extract from the liver and lung.
Using their extraction method we compared the levels of
lung and liver IL-13 in IL-13R 2 /  and IL-13R 2 / 
mice and found that levels of tissue IL-13 are significantly
elevated in IL-13R 2 /  mice compared with IL-13R 2 / 
mice (Fig. 3 C). Taken together, these results suggest that
the presence of IL-13R 2 is required to regulate the levels
of serum and tissue IL-13.
Serum IgE, IgA, IgG2a, and IgG2b, and Immune-dependent
IFN-  Production Are Elevated in IL-13R 2    Mice. IgE
levels are increased in both IL-4–deficient IL-13 transgenic
mice and in IL-4–deficient mice infected with malaria (23,
29). Similarly, an increased level of serum IgE is observed
in mice after the administration of IL-13 (4). Therefore, we
wished to study the effect of IL-13R 2 deficiency on se-
rum Ig isotype levels. Fig. 4 A shows that serum IgA, IgE
and IgG2a, and IgG2b are significantly elevated in IL-
13R 2 /  mice. IL-13 has been shown to affect the func-
tion of accessory cells such as B cells (30) and macrophages
(15), and IL-13 deficiency has been shown to impair Th2
differentiation (31). In contrast, IL-13 has not been dem-
onstrated to function directly on T cells. Therefore, we ex-
amined cytokine production from spleen cells in response
to activation with anti-CD3 in IL-13R 2 /   and  IL-
13R 2 /  mice. Fig. 4 B shows that the level of IFN-  is
increased nearly twofold in spleen cultures from IL-
13R 2 /  mice whereas IL-13 (Fig. 3 C) levels are only
slightly decreased and IL-10 levels slightly increased. Taken
together, these results suggest that IL-13R 2 serves to at-
tenuate levels of IFN-  and the downstream Ig serum iso-
types that are regulated by IFN-  and IL-13.
Bone Marrow Macrophage Progenitors Are Increased from IL-
13R 2    Mice. IL-13 and parasite-treated mice display
peripheral monocytosis and extramedullary hematopoiesis
(19). To determine if IL-13R 2 plays a role in bone mar-
row macrophage development we determined the fre-
quency of hematopoietic cell progenitors in bone marrow
methylcellulose cultures. As shown in Fig. 5 A, IL-
13R 2 /  mice had significantly higher frequencies of
bone marrow macrophage progenitors per femur as dem-
onstrated by increased macrophage colony formation. In
addition, frequencies of immature erythroid (as measured
by burst forming unit erythroid) progenitors per femur
were significantly reduced. However, examination of im-
mature bone marrow erythroid precursor (TER-119) fre-
quency, splenic colony formation and peripheral blood
lymphocyte populations failed to show differences (unpub-
lished data). These results are similar to that seen when IL-
13 is administered to mice (19) and are consistent with en-
hanced IL-13 activity in the absence of IL-13R 2.
Peritoneal Macrophages from IL-13R 2    Mice Release Less
NO and IL-12 in Response to LPS than IL-13R 2   
Mice. To address the hypothesis that deficiency of IL-
13R 2 might affect mature macrophage function, we
compared the ability of IL-13R 2 /  and  IL-13R 2 / 
resident peritoneal macrophages (RPM) to generate NO in
response to IFN-  and LPS. Pretreatment of mouse bone
Figure 2. STAT6 signaling is preserved in IL-13R 2 /  mice in re-
sponse to IL-13 in fibroblasts that express IL-13 receptor transcripts. (A)
IL-13 receptor transcripts are expressed by MLF. RPA was performed
with total RNA from passage 15 MLF untreated or treated for 24 h with
IL-4 or IL-13. Transcripts are identified according to molecular weight of
free probe in marker lane. (B) STAT6 signaling is intact in lung fibroblasts
from  IL-13R 2 /  mice. MLF from IL-13R 2 /  and  IL-13R 2 / 
mice respond to IL-13 with STAT6 activation as shown by EMSA. Fibro-
blasts grown from the lung of IL-13R 2 /  and IL-13R 2 /  mice were
stimulated with 100 ng/ml IL-4 or 100 ng/ml IL-13 for 15 min. Cyto-
plasmic extracts and 32P-labeled probe were incubated with or without
anti-STAT1 or anti-STAT6. In the presence of anti-STAT6 the complex
migration is retarded (arrow) compared with samples without Ab.
Figure 3. Tissue and immune but
not serum IL-13 expression is pre-
served in IL-13R 2 /  mice. Sera
(A) and lung and liver tissue homog-
enates (C) from 8–20 individual IL-
13R 2 /   and  IL-13R 2 /   mice
were assayed by ELISA for IL-13.
(B) 4   106/ml spleen cells pooled
from four to five mice were pooled
and incubated with 0.1 ug/ml anti-
CD3. 72 h after stimulation, cell su-
pernatants from triplicate wells were
harvested and assayed by ELISA for
IL-13. Data are representative of at least three experiments, multiple groups with five mice per group, and are given as mean values   SEM. P values for
significant difference between groups as determined by Student’s unpaired, two-tailed t test are noted.T
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marrow macrophages or peritoneal macrophages with IL-
13 or IL-4 has been shown to suppress IFN- –induced
NO production in a STAT6-dependent fashion (15, 32,
33). Consistent with preserved STAT6 activation in fibro-
blasts, we observed that pretreatment of RPM from IL-
13R 2 /  and IL-13R 2 /  mice resulted in a depression
of NO (unpublished data). Fig. 5 B shows that NO pro-
duction is less in IL-13R 2 /   RPM compared with
13R 2 /  RPM after combined IFN-  and LPS activa-
tion. Higher doses of LPS are required to induce NO in
IL-13R 2 /  mice demonstrating that macrophages from
IL-13R 2 /   mice are less sensitive to LPS than IL-
13R 2 /  mice.
IL-13 treatment of macrophages in vitro before or coin-
cident with exposure to LPS has been shown to modulate
production of proinflammatory cytokines such at IL-6,
TNF, and IL-12, and the antiinflammatory cytokine IL-10
(15–17). However, the consequence of IL-13 treatment in
these investigations varies depending on the nature and
culture conditions of the macrophages being studied. In
contrast, systemic administration of IL-13 before exposure
to LPS in vivo has consistently been shown to protect
mice from endotoxemia and is associated with decreased
TNF, IFN- , IL-12, and IL-10 production (20–22). Con-
sistent with these results, we also observed that pretreat-
ment of RPM from IL-13R 2 /  and IL-13R 2 /  mice
resulted in a depression of LPS-induced TNF production
(unpublished data). Therefore, we wished to study the ef-
fect of LPS on cytokine production from IL-13R 2 / 
and IL-13R 2 /  RPM. Fig. 5 C shows that IL-12 pro-
duction is decreased in IL-13R 2 /  RPM. IL-10 and
TGF-  are not changed in IL-13R 2 /  RPM. TNF- 
levels from IL-13R 2 /  RPM were variable and slightly
increased as shown in this experiment and slightly de-
creased in other experiments.
Discussion
In this report we describe the generation of mice defi-
cient in IL-13R 2 to define the role of this receptor chain
in IL-13 responses. IL-13R 2 may act to modulate the ef-
fects of IL-13 in vivo in various ways. IL-13R 2 could en-
hance IL-13 activities by increasing the strength of IL-13
Figure 4. Serum IgE, IgA, IgG2a, and IgG2b, and immune-dependent
IFN-  production are elevated in IL-13R 2 /  mice. (A) Analysis of
wild-type serum Ig isotypes. Sera from 24–32 individual animals were an-
alyzed. Data represent mean of triplicate wells. **, P   0.0001 for IgE,
IgA, Ig2a, and Ig2b. (B) Cytokine production from anti-CD3–activated
spleen cells. 4   106/ml spleen cells pooled from four to five mice and in-
cubated with 0.1 ug/ml anti-CD3. 72 h after stimulation, cell superna-
tants from triplicate wells were harvested and assayed by ELISA for cyto-
kines. Data are representative of at least three experiments, multiple
groups with five mice per group, and are given as mean values   SEM. *,
significant difference between groups as determined by Student’s un-
paired, two-tailed t test; *, P   0.0001.
Figure 5. Tissue macrophage progenitors are increased in IL-13R 2 / 
mice and produce less NO in response to LPS. (A) Bone marrow mac-
rophage progenitors are increased in IL-13R 2 /  mice. Bone marrow
from three IL-13R 2 /  and IL-13R 2 /  mice was harvested and cul-
tured separately as described in Materials and Methods. Colony morphol-
ogy and frequency were determined using an inverted microscope. Data
represent three mice per group and are given as mean values   SEM. *P  
0.05, significant difference between groups as determined by Student’s
unpaired, two-tailed t test. (B) Activation-induced tissue macrophage NO
is attenuated in IL-13R 2 /  mice. Levels of macrophage NO detected
after 48 h from pooled cultures of four to five mice stimulated with in-
creasing concentration of LPS and constant level of IFN-  at 20 ng/ml.
Data are representative of at least five experiments. (C) Activation-
induced IL-12 but not TNF- , TGF- , IL-10, nor IL-6 is attenuated in
IL-13R 2 /  mice. Level of IL-12 detected after 48 h by macrophages
stimulated with increasing concentration of LPS and constant level of
IFN-  at 20 ng/ml. Data are representative of at least five experiments.T
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signaling or attenuate IL-13 effects by negative signaling or
simply as a molecular decoy. Attenuating roles of IL-
13R 2 could explain the lack of evidence for IL-13 effects
on T cells or an enhancing role could explain the effect of
IL-13 effect on airways hyperreactivity and eosinophil sur-
vival distinct from IL-4.
Interestingly, we find that the absence of IL-13R 2 cor-
relates with nearly complete loss of serum IL-13 and an in-
crease in tissue IL-13 in IL-13R 2 /  mice. The lack of se-
rum IL-13 cannot be explained by a lack of IL-13
production in IL-13R 2 /  mice as IL-13 is present in tis-
sues of IL-13R 2 /  and is produced by activated IL-
13R 2 /  immune cells. Serum IL-13R 2 may act as a
reservoir for serum IL-13 and extend IL-13 half-life or may
function as a natural antagonist of IL-13 as has been shown
for IL-4 receptor (34, 35). We have previously shown that
the administration of IL-13R 2.Fc is effective as an antag-
onist of IL-13 in vivo (6, 36). In addition, increased tissue
IL-13 in IL-13R 2 /   mice cannot be explained by
slightly decreased levels of immune IL-13 production. This
suggests that in the liver and lung, IL-13R 2 acts to de-
crease tissue cytokine levels, possibly via equilibrium with
the serum reservoir. Finally, IL-13 appears to regulate the
expression of IL-13R 2, suggesting that ligand and recep-
tor may cross regulate one another.
We find that serum IgE, IgG2a, IgG2b, and IgA levels
are increased in IL-13R 2 /  mice. Lai and Mosmann (30)
have shown that the administration of IL-13 in vivo en-
hances plasma levels of IgG2a and IgG2b and B cell survival
in vitro. Concurrent changes in IgE may not have been de-
tected in their studies due to assay sensitivity (30). Increased
serum IgE independent of IL-4 was demonstrated in trans-
genic mice overexpressing IL-13 (23). Conversely, Bost et
al. (37) have shown that mice treated with anti–IL-13 dur-
ing oral immunization have significantly reduced intestinal
IgA, serum IgA, and serum IgG. Taken together, these data
suggest that IL-13 can enhance IgE, IgG2a, IgG2b, and IgA
levels in vivo and are consistent with an enhanced IL-13
response in IL-13R 2–deficient mice.
Here, we show that IL-13R 2 /  mice have increased
macrophage progenitors and decreased tissue macrophage
NO and IL-12 production. This is similar to previous stud-
ies showing that IL-13 administration in vivo affects mono-
cyte/macrophage development and reduces the sensitivity
of mice to LPS-induced shock (20–22). In addition, the
decreased responsiveness of immune cells to LPS in IL-
13R 2 /  mice, as shown by decreased expression of IL-
12, is similar to studies in vivo showing a diminished re-
sponse to LPS after the administration of IL-13 (20). Levels
of IL-10, TGF- , and prostaglandin E2 (unpublished data),
and IL-4 production are similar from IL-13R 2 / – and
IL-13R 2 / –derived macrophages and spleen cells and
cannot explain the decreased production of NO in re-
sponse to LPS and IFN- .
Taken together, our studies indicate that overall IL-
13R 2 serves to dampen IL-13–mediated responses in
vivo. The absence of this receptor results in decreased re-
sponsiveness to LPS, increased levels of bone marrow mac-
rophage progenitors, and enhanced levels of serum IgA,
IgE, IgG2a, and IgG2b in wild-type mice. All of these ef-
fects are consistent with enhanced IL-13 responses in vivo.
This interpretation is also consistent with the enhancement
of IL-13–mediated fibrosis observed in Schistosoma mansoni–
infected  IL-13R 2 /  mice (38). These studies serve to
underscore the potent role IL-13 plays in both wild-type
mice and in mice undergoing vigorous immune responses
to pathogens and the necessity for precise control of IL-13
levels in vivo.
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